BL22 immunotoxin

SUSPENDED · PHASE1 · Leukemia, Lymphoma

protocol development and Amended protocol revision

Scientific benefit, asset-specific safety, ownership and licensing: Unknown without reviewed evidence.

Detailed evidence is available in the local Pro plan simulation.